Exagen Inc. (XGN) Tops Q1 EPS by 5c ; Offers Guidance

Exagen Inc. (NASDAQ: XGN) reported Q1 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $17.31 million versus the consensus estimate of $16.41 million.

GUIDANCE:

Exagen Inc. sees FY 2026 revenue of $70-73 million, versus the consensus of $71.27 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00